Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced Dr. Iman Barilero as the new Chief Regulatory Officer, effective June 1, 2021. Dr. Barilero brings over 30 years of regulatory experience, having successfully guided numerous drug approvals in various global markets. She previously served as Senior Advisor to Innouvo and held key positions at Agenus, Poxel, and Lundbeck. Her expertise aligns with Solid’s mission to enhance therapies for Duchenne muscular dystrophy, particularly focusing on SGT-001 and SGT-003. The company aims to develop differentiated therapies through innovative regulatory strategies.

Positive

• Dr. Iman Barilero's appointment is expected to bring a wealth of regulatory expertise, enhancing the company's drug development strategies.
• Barilero's extensive experience includes successful regulatory approvals which could contribute to Solid's goals in developing therapies for Duchenne muscular dystrophy.

Negative

• None.

CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulatory Officer, effective June 1, 2021.

Dr. Barilero brings three decades of experience as a strategic executive in the healthcare industry, successfully designing innovative and integrated regulatory pathways that gained regulatory approvals for new molecular entities in various areas of unmet medical needs across all phases of development in the U.S., EU, Switzerland, China, Japan and Brazil.

“Dr. Barilero comes to us with a wealth of experience in drug development and regulatory science, and the combination of her expert knowledge and passion to impact patients’ lives through her work is perfectly aligned with our mission of improving the lives of patients with Duchenne,” said Ilan Ganot, Co-Founder, President and Chief Executive Officer of Solid Biosciences.

Dr. Barilero was most recently Senior Advisor to Innouvo providing strategic regulatory guidance to scientific ventures. Prior to her most recent position, she held senior positions in Regulatory Affairs and Pharmacovigilance at Agenus and Poxel in Boston. Previously, she was Vice President, Global Head Regulatory Science & Policy at Lundbeck A/S where she played a key role in influencing the external medical and regulatory policy environment that enabled the regulatory approval of Selincro, Trintellix and contributing to approval of Rexulti and Abilify Maintena in CNS disorders. Earlier in her career, she held various leadership roles of increasing responsibility in Pharmacology, Clinical Science, Pharmacovigilance, Regulatory Affairs & Policy engagement at Johnson & Johnson, Roche, Wyeth and Bristol Myers Squibb. She started her career as a Researcher at Gustave Roussy in France, the leading European Cancer Center.

Dr. Barilero received her Doctorate of Pharmacy & Pharmaceutical Chemistry from the University of Damascus, Syria and her Master of Science and Doctor of Philosophy degrees in Molecular & Cellular Pharmacology, Oncology from the University of Paris VI.

“With its deep commitment to patients and an approach to drug development that focuses on outcomes that are meaningful to the Duchenne community, I believe that Solid Biosciences shares the values that have driven me throughout my life and career,” said Dr. Barilero. “The company culture embraces an innovative regulatory strategy, through cross-functional collaboration that integrates scientific rationale, clinical value and patient needs, which I believe will enable the development of differentiated therapies for neuromuscular disorders, including SGT-001 and SGT-003. I look forward to working with the other dedicated members of the management team to achieve this vision.”

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Caitlin Lowie
Solid Biosciences
607-423-3219
Clowie@solidbio.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com

FAQ

Who is the new Chief Regulatory Officer of Solid Biosciences?

Dr. Iman Barilero has been appointed as the Chief Regulatory Officer of Solid Biosciences, effective June 1, 2021.

What experience does Dr. Iman Barilero have?

Dr. Barilero has over 30 years of experience in the healthcare industry, focusing on regulatory pathways and drug approvals in multiple countries.

What is Solid Biosciences' focus with their therapies?

Solid Biosciences is focused on developing therapies for Duchenne muscular dystrophy, with a particular emphasis on gene therapy candidates SGT-001 and SGT-003.

How might Dr. Barilero's appointment impact Solid Biosciences?

Dr. Barilero's regulatory expertise may enhance Solid's ability to navigate approval processes for its therapies, potentially accelerating their development.